Davita Inc (NYSE:DVA) was the recipient of unusually large options trading on Monday. Stock traders purchased 7,622 put options on the company. This represents an increase of 1,114% compared to the average volume of 628 put options.
NYSE DVA opened at $68.57 on Tuesday. The firm has a market cap of $11.29 billion, a P/E ratio of 20.65, a P/E/G ratio of 0.87 and a beta of 1.09. The company has a current ratio of 1.90, a quick ratio of 1.88 and a debt-to-equity ratio of 1.82. Davita has a fifty-two week low of $52.51 and a fifty-two week high of $80.71.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. United Asset Strategies Inc. lifted its position in Davita by 13.0% during the second quarter. United Asset Strategies Inc. now owns 6,405 shares of the company’s stock valued at $445,000 after purchasing an additional 735 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in Davita by 4.5% during the second quarter. Janney Montgomery Scott LLC now owns 19,009 shares of the company’s stock valued at $1,320,000 after purchasing an additional 811 shares in the last quarter. Northstar Group Inc. lifted its position in Davita by 7.8% during the third quarter. Northstar Group Inc. now owns 11,684 shares of the company’s stock valued at $837,000 after purchasing an additional 850 shares in the last quarter. Vident Investment Advisory LLC raised its holdings in Davita by 1.5% during the second quarter. Vident Investment Advisory LLC now owns 57,294 shares of the company’s stock valued at $3,979,000 after acquiring an additional 872 shares during the period. Finally, IFM Investors Pty Ltd raised its holdings in Davita by 13.0% during the third quarter. IFM Investors Pty Ltd now owns 7,958 shares of the company’s stock valued at $570,000 after acquiring an additional 915 shares during the period. Institutional investors own 87.36% of the company’s stock.
A number of equities analysts have recently issued reports on DVA shares. Zacks Investment Research upgraded Davita from a “hold” rating to a “buy” rating and set a $81.00 price target on the stock in a research note on Monday, October 8th. JPMorgan Chase & Co. upgraded Davita from an “underweight” rating to a “neutral” rating in a research note on Thursday, September 13th. Finally, ValuEngine upgraded Davita from a “hold” rating to a “buy” rating in a research note on Tuesday, October 9th. Six research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $82.50.
TRADEMARK VIOLATION WARNING: “Investors Purchase High Volume of Put Options on Davita (DVA)” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/11/06/investors-purchase-high-volume-of-put-options-on-davita-dva.html.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
See Also: Return on Investment (ROI)
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.